Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original 2016 ALBI-T score

An additive 0-5 score combining original ALBI grade with LCSGJ fifth-edition TNM stage.

Evidence-based context for fast calculator use

Purpose:
Interpret the historical ALBI-T score in its source-specific hepatocellular carcinoma context.
Population:
Confirmed HCC at initial treatment-naive assessment with contemporaneous original ALBI grade and complete externally assigned LCSGJ fifth-edition TNM stage.
Factors:
Original ALBI grade, LCSGJ fifth-edition TNM stage, Source/version provenance, Baseline timing
Reference:
Hiraoka A, et al. J Gastroenterol Hepatol. 2016. DOI 10.1111/jgh.13250. PMID 26647219.
HomeOriginal 2016 ALBI-T Score using LCSGJ Fifth-Edition TNM
Pin your most used calculators here by clicking the star in the dropdown.

Original 2016 ALBI-T Score using LCSGJ Fifth-Edition TNM

Clinical Context & Background

This source-locked interpreter implements the original ALBI-T score reported by Hiraoka and colleagues in 2016. It adds original ALBI grade points (Grade 1/2/3 = 0/1/2) to Liver Cancer Study Group of Japan fifth-edition TNM stage points (I/II/III/IVA/IVB = 0/1/2/3/3), producing an integer score from 0 to 5.
Both upstream classifications must already be complete, contemporaneous, and independently assigned. This route does not calculate ALBI from laboratory values, derive or translate TNM stage, accept partial T category, or substitute AJCC/UICC or another LCSGJ edition. Modified ALBI, mALBI-T, acute liver failure, transplant priority, post-treatment reassessment, individualized survival medians, and treatment selection are outside scope.
Primary Source EvidenceHiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031-1036. DOI: 10.1111/jgh.13250. PMID: 26647219.
Formula Logic
ALBI-T = original ALBI grade points (Grade 1/2/3 = 0/1/2) + LCSGJ fifth-edition TNM stage points (I/II/III/IVA/IVB = 0/1/2/3/3). Range 0-5.

Reference Data

ALBI-T totalSource-defined output
0Historical additive score 0
1Historical additive score 1
2Historical additive score 2
3Historical additive score 3
4Historical additive score 4
5Historical additive score 5

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Only after original ALBI grade and complete LCSGJ fifth-edition TNM stage have been independently assigned at the same initial pretreatment assessment.
  • Only for confirmed hepatocellular carcinoma in the historical source context.

How To Interpret

  • The output is the exact integer sum of the two source lookups, from 0 through 5.
  • The score is a historical cohort stratification label, not an individualized survival estimate.

What To Do Next

  • Document the upstream ALBI and TNM source versions and interpret the score with current multidisciplinary assessment.

Limitations

  • Does not calculate original ALBI grade or LCSGJ TNM stage.
  • Do not substitute another TNM edition/system, partial T category, mALBI, or mALBI-T.
  • Not applicable after treatment or recurrence, to other tumors, acute liver failure, or transplant-priority decisions.
  • Does not provide treatment recommendations or individual survival medians.

Validated Population

Historical Japanese HCC cohort assessed at initial treatment using original ALBI grade and LCSGJ fifth-edition TNM.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed ALBI-T cases passed through visible production controls at scores 0, 2, and 5, including the Stage IVB maximum branch.
    • No unexpected N/A, literal undefined value, stale control, unsupported risk gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/albi-t-liver-function-tumor-burden-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/albi-t-liver-function-tumor-burden.json.

  3. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  4. : Full validation completed

    • 512/512 deterministic source-table, strict-contract, applicability, trace, UI/reset, isolation, registry, and report assertions passed with zero score mismatch.
    • This verifies software implementation of the source-locked model; it is not prospective clinical validation or medical advice.

  5. : Scope and interpretation corrected

    • Restricted interpretation to confirmed HCC at initial treatment-naive assessment with contemporaneous source components.
    • Removed Good/Intermediate/Poor labels, individual survival implications, treatment selection, transplant priority, and acute-liver-failure claims.

    Included in the current validation report.

  6. : Calculation and input contract corrected

    • Replaced favorable defaults and numeric coercion with an exact immutable eight-own-key contract.
    • Corrected the score to ALBI grade minus one plus LCSGJ fifth-edition TNM stage points, including distinct IVA and IVB inputs that each contribute three points.

    Included in the current validation report.

  7. : Model identity and citation corrected

    • Locked the permanent route to the original 2016 Hiraoka ALBI-T score using original ALBI and LCSGJ fifth-edition TNM.
    • Separated later modified ALBI and mALBI-T models and corrected the primary citation and PMID.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

ALBI ScoreBCLC 2026 Hepatocellular Carcinoma StageOriginal Hong Kong Liver Cancer Staging System (HKLC-9, 2014)

Frequently Asked Questions

When should Original 2016 ALBI-T Score using LCSGJ Fifth-Edition TNM be used?

Use it for patients undergoing liver-function, hepatocellular carcinoma staging, imaging, or transplant assessment when all required inputs and the intended clinical setting are confirmed.

Can Original 2016 ALBI-T Score using LCSGJ Fifth-Edition TNM determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.